Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Skin Cancer01:30

Skin Cancer

Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reply to: The chemotherapeutic drug CX-5461 is a potent mutagen in cultured human cells.

medRxiv : the preprint server for health sciences·2025
Same author

Microbiota-derived butyrate promotes a FOXO1-induced stemness program and preserves CD8<sup>+</sup> T cell immunity against melanoma.

Immunity·2025
Same author

The development of a risk stratification tool for localized melanomas through the integrated application of supervised and unsupervised machine learning techniques.

Journal of the American Academy of Dermatology·2025
Same author

Neoadjuvant or perioperative therapy for melanoma metastasis in clinical practice: an international survey.

The Lancet. Oncology·2025
Same author

Blending space and time to talk about cancer in extended reality.

NPJ digital medicine·2024
Same author

Patient Experience of Complex Genomic Sequencing Exploring Patient Preference, Barriers, and Enablers for Delivery.

JCO precision oncology·2024

Related Experiment Video

Updated: Jul 13, 2026

A 3D Organotypic Melanoma Spheroid Skin Model
08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

Dermatofibrosarcoma protuberans: recent clinical progress.

Grant McArthur1

  • 1Peter MacCallum Cancer Centre, St Andrews Place, East Melbourne, Australia, 3002. grant.mcarthur@petermac.org

Annals of Surgical Oncology
|July 25, 2007
PubMed
Summary

Dermatofibrosarcoma protuberans (DFSP) is a rare skin cancer. Imatinib shows promise in treating unresectable, advanced DFSP by targeting platelet-derived growth factor receptor (PDGFR).

Area of Science:

  • Oncology
  • Dermatology
  • Molecular Biology

Background:

  • Dermatofibrosarcoma protuberans (DFSP) is a rare, slow-growing skin tumor with a high local recurrence rate.
  • Metastasis occurs in up to 5% of DFSP patients despite optimal surgical management.
  • The t(17;22) translocation in DFSP constitutively activates platelet-derived growth factor receptor (PDGFR).

Purpose of the Study:

  • To review the current understanding of DFSP pathogenesis and management.
  • To evaluate the role of tyrosine kinase inhibitors in treating advanced DFSP.
  • To highlight the implications of molecular-level pathogenetic events for DFSP treatment strategies.

Main Methods:

  • Review of current literature on Dermatofibrosarcoma protuberans (DFSP).
  • Emphasis on molecular pathogenetic events and their management implications.

Related Experiment Videos

Last Updated: Jul 13, 2026

A 3D Organotypic Melanoma Spheroid Skin Model
08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

  • Evidence synthesis for tyrosine kinase inhibition in unresectable, locally advanced, or metastatic DFSP.

    • Main Results:

    • Wide surgical resection remains the primary treatment for DFSP.
    • Imatinib, a PDGFR inhibitor, has demonstrated significant efficacy in treating advanced DFSP.
    • Complete or partial remissions have been observed in most patients treated with imatinib for advanced DFSP.

    Conclusions:

    • Imatinib is approved for unresectable, recurrent, or metastatic DFSP in patients ineligible for surgery.
    • Future research will explore imatinib's potential in the neoadjuvant setting.
    • Neoadjuvant imatinib may reduce tumor volume, enabling surgical resection of large DFSP.